Holen Sie sich die Stockscreener-App
31.10
1.21%
-0.38
Handel nachbörslich:
31.55
0.45
+1.45%
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug. - Pluang
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target - TradingView
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex's Barzolvolimab Hits Mark in Two Phase 3 Trials for Chronic Hives - finance.biggo.com
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ - tradingview.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - Yahoo Finance
Celldex sinks as safety concerns cloud immune drug results - Yahoo Finance
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - The Pharma Letter
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - Yahoo Finance
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex reports positive phase 3 trial results for CSU drug By Investing.com - Investing.com Canada
Celldex reports strong Phase 3 data in urticaria - TipRanks
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex stock rises after positive phase 3 trial results By Investing.com - Investing.com Canada
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - TradingView
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex (CLDX) Q2 2026 Earnings: The Available Earnings Metric Delivers a Beat in Latest Trading; Post-Earnings: The Stock Records a 1.60% Increase at the CloseGuidance Downgrade Alert - dars.gov.et
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Prime Publishers, Inc.
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):